Abstract
Immunosuppressive therapy in transplantation remains rather unspecific with known side effects of a generally suppressed immune system. Studies provided clear evidence for an increased susceptibility for infections and also cancer in the immunosuppressed patient population. One possible way to address this problem is the discovery of agents with both immunosuppressive and anti-cancer properties. Here, we tested the effect of rapamycin versus cyclosporine on tumor growth and graft survival in transplanted mice simultaneously bearing tumors. In one model, C57B1/6 mice received subcutaneous implants of syngenic B16 melanoma cells; 7 days later a vascularized heterotopic C3H heart transplant was performed. In a second model, BALB/ c mice received subcutaneous syngenic CT-26 colon adenocarcinoma cells 7 days before C3H “ear-heart” transplantation. Rapamycin or cyclosporine treatment was initiated also on day 7 after tumor-implantation. In the C57B1/6 model, B16 tumors grew for 2–3 weeks before mice died from tumor complications. However, rapamycin treatment protected allografts, permitted animal survival, and inhibited tumor growth. In contrast, cyclosporine-treated mice died from advancing tumors, albeit, with a functioning allograft. Similar findings were observed with CT-26 tumors and “ear-heart”-transplants in Balb/c mice.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Meyer CG, Penn I, James L (2000) Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69:1633–1637
Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403
Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B (2001) De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 7: S109–S118
Guba M, von Breitenbuch P, Steinbauer M, Köhl G, Flegel S, Hornung M (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128–135
Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530–534
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Andrassy, J. et al. (2004). Rapamycin verhindert Abstossung und Tumorwachstum in einem Tumor-Transplantations-Modell in der Maus. In: Ulrich, B., Jauch, KW., Bauer, H., Menger, M.D., Laschke, M., Slotta, J. (eds) Chirurgisches Forum 2004. Deutsche Gesellschaft für Chirurgie, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18547-2_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-18547-2_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20027-7
Online ISBN: 978-3-642-18547-2
eBook Packages: Springer Book Archive